- Previous Close
0.2300 - Open
0.2200 - Bid 0.2150 x --
- Ask 0.2200 x --
- Day's Range
0.2150 - 0.2300 - 52 Week Range
0.1700 - 0.4300 - Volume
31,700 - Avg. Volume
107,881 - Market Cap (intraday)
19.032M - Beta (5Y Monthly) 3.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
www.pharmather.comRecent News: PHRM.CN
View MorePerformance Overview: PHRM.CN
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHRM.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHRM.CN
View MoreValuation Measures
Market Cap
19.03M
Enterprise Value
17.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.62%
Return on Equity (ttm)
-71.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.16M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.84M